Current Status of BTKi Treatment for CLL/SLL in China
NCT06508684
·
clinicaltrials.gov ↗
RECRUITING
Status
1000
Enrollment
OTHER
Sponsor class
Conditions
CLL/SLL
Interventions
DRUG:
BTK inhibitor
Sponsor
The First Affiliated Hospital with Nanjing Medical University